Image Credit: STAT News
STAT+: GSK blood cancer therapy, once pulled from the market, is approved in the U.K.
GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was withdrawn several years ago.